Bausch Health Companies (TSE:BHC) has released an update.
Bausch Health Companies Inc. reported a strong start to 2024, with first-quarter revenues increasing by 11% to $2.15 billion, marking the fourth consecutive quarter of year-over-year growth. The company also highlighted a milestone in its business developments with the appeal decision regarding Xifaxan®, which is a key step towards the full separation of Bausch + Lomb. Despite a GAAP net loss of $64 million, Bausch Health’s adjusted EBITDA rose by 13% to $665 million, reaffirming its full-year financial guidance.
For further insights into TSE:BHC stock, check out TipRanks’ Stock Analysis page.
